Bulletin
Investor Alert

Regeneron Pharmaceuticals Inc.

NAS: REGN

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Jan 28, 2022, 7:49 p.m.

/zigman2/quotes/203149337/composite

$

622.16

Change

-2.76 -0.44%

Volume

Volume 21,756

Quotes are delayed by 20 min

/zigman2/quotes/203149337/composite

Previous close

$ 608.72

$ 624.92

Change

+16.20 +2.66%

Day low

Day high

$601.89

$625.00

Open

52 week low

52 week high

$441.00

$686.62

Open

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accele...

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Valuation

P/E Current

19.94

P/E Ratio (with extraordinary items)

9.91

P/E Ratio (without extraordinary items)

15.83

Price to Sales Ratio

6.54

Price to Book Ratio

4.69

Price to Cash Flow Ratio

21.24

Enterprise Value to EBITDA

16.94

Enterprise Value to Sales

4.77

Total Debt to Enterprise Value

0.05

Efficiency

Revenue/Employee

931,393.00

Income Per Employee

385,093.00

Receivables Turnover

2.50

Total Asset Turnover

0.53

Liquidity

Current Ratio

3.63

Quick Ratio

2.91

Cash Ratio

1.33

Profitability

Gross Margin

84.04

Operating Margin

42.09

Pretax Margin

44.84

Net Margin

41.35

Return on Assets

21.98

Return on Equity

31.77

Return on Total Capital

28.02

Return on Invested Capital

27.53

Capital Structure

Total Debt to Total Equity

24.45

Total Debt to Total Capital

19.65

Total Debt to Total Assets

15.71

Long-Term Debt to Equity

24.45

Long-Term Debt to Total Capital

19.65

Officers and Executives

Name Age Officer Since Title
Dr. P. Roy Vagelos 90 1995 Chairman
Dr. Leonard S. Schleifer 66 1988 President, Chief Executive Officer & Director
Dr. George Damis Yancopoulos 59 1989 Co-President, Director & Chief Scientific Officer
Ms. Patrice Gilooly - 1998 Senior VP-Quality Assurance & Operations
Mr. Robert E. Landry 55 2013 Chief Financial Officer & Executive VP-Finance

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/03/2022 George L. Sing
Director
191   Award at $0 per share. 0
01/03/2022 Arthur Frederick Ryan
Director
191   Award at $0 per share. 0
01/03/2022 Michael S. Brown
Director
191   Award at $0 per share. 0
01/03/2022 Joseph L. Goldstein
Director
191   Award at $0 per share. 0
01/03/2022 Marc Tessier-Lavigne
Director
191   Award at $0 per share. 0
01/03/2022 Christine A. Poon
Director
191   Award at $0 per share. 0
01/03/2022 N. Anthony Coles
Director
191   Award at $0 per share. 0
01/03/2022 Huda Y. Zoghbi
Director
191   Award at $0 per share. 0
01/03/2022 Bonnie L. Bassler
Director
191   Award at $0 per share. 0
01/03/2022 Marion McCourt
EVP Commercial
1,000   Derivative/Non-derivative trans. at $342.93 per share. 342,930
01/03/2022 Arthur Frederick Ryan
Director
2   Disposition at $628.87 per share. 1,257
01/03/2022 Arthur Frederick Ryan
Director
6   Disposition at $627.22 per share. 3,763
01/03/2022 Arthur Frederick Ryan
Director
5   Disposition at $626.48 per share. 3,132
01/03/2022 Arthur Frederick Ryan
Director
45   Disposition at $625.56 per share. 28,150
01/03/2022 Arthur Frederick Ryan
Director
14   Disposition at $624.3 per share. 8,740
01/03/2022 Arthur Frederick Ryan
Director
19   Disposition at $623.62 per share. 11,848
01/03/2022 Arthur Frederick Ryan
Director
8   Disposition at $622.52 per share. 4,980
01/03/2022 Arthur Frederick Ryan
Director
1   Disposition at $621.98 per share. 621
01/03/2022 Marion McCourt
EVP Commercial
1,000   Disposition at $625 per share. 625,000
12/22/2021 George Damis Yancopoulos
President and Chief Scientific; Director
150,182   Derivative/Non-derivative trans. at $610.04 per share. 91,617,027
12/22/2021 George Damis Yancopoulos
President and Chief Scientific; Director
159,915   Derivative/Non-derivative trans. at $610.04 per share. 97,554,546
12/22/2021 George Damis Yancopoulos
President and Chief Scientific; Director
203,204   Derivative/Non-derivative trans. at $270.43 per share. 54,952,457
12/22/2021 George Damis Yancopoulos
President and Chief Scientific; Director
239,063   Derivative/Non-derivative trans. at $179.13 per share. 42,823,355
12/16/2021 P. Roy Vagelos
Director
107   67,948
12/16/2021 P. Roy Vagelos
Director
19   12,059
12/13/2021 Robert E. Landry
EVP Finance CFO
116   Disposition at $662.5 per share. 76,850
12/13/2021 Marion McCourt
EVP Commercial
344   Disposition at $653.12 per share. 224,673
12/11/2021 Neil Stahl
EVP Research and Development
753   Derivative/Non-derivative trans. at $664.34 per share. 500,248
12/11/2021 Andrew J. Murphy
EVP Research
697   Derivative/Non-derivative trans. at $664.34 per share. 463,044
12/11/2021 Christopher Robert Fenimore
SVP Controller
270   Derivative/Non-derivative trans. at $664.34 per share. 179,371
12/11/2021 Daniel P. van Plew
EVP & General Mgr, Industrial
697   Derivative/Non-derivative trans. at $664.34 per share. 463,044
12/11/2021 Robert E. Landry
EVP Finance CFO
697   Derivative/Non-derivative trans. at $664.34 per share. 463,044
12/11/2021 Joseph J. LaRosa
EVP General Counsel and Secret
697   Derivative/Non-derivative trans. at $664.34 per share. 463,044
12/11/2021 Marion McCourt
EVP Commercial
388   Derivative/Non-derivative trans. at $664.34 per share. 257,763
12/10/2021 Andrew J. Murphy
EVP Research
38   Disposition at $672.3 per share. 25,547
12/10/2021 Andrew J. Murphy
EVP Research
219   Disposition at $671.33 per share. 147,021
12/10/2021 Andrew J. Murphy
EVP Research
872   Disposition at $670.68 per share. 584,832
12/10/2021 Andrew J. Murphy
EVP Research
1,018   Disposition at $669.6 per share. 681,652
12/10/2021 Andrew J. Murphy
EVP Research
1,738   Disposition at $668.42 per share. 1,161,713
12/10/2021 Andrew J. Murphy
EVP Research
280   Disposition at $667.5 per share. 186,900
12/10/2021 Andrew J. Murphy
EVP Research
384   Disposition at $666.4 per share. 255,897
12/10/2021 Andrew J. Murphy
EVP Research
404   Disposition at $665.29 per share. 268,777
12/10/2021 Andrew J. Murphy
EVP Research
158   Disposition at $664.28 per share. 104,956
12/10/2021 Andrew J. Murphy
EVP Research
272   Disposition at $663.61 per share. 180,501
12/10/2021 Andrew J. Murphy
EVP Research
354   Disposition at $662.36 per share. 234,475
12/10/2021 Andrew J. Murphy
EVP Research
282   Disposition at $661.57 per share. 186,562
12/10/2021 Andrew J. Murphy
EVP Research
4   Disposition at $660.45 per share. 2,641
12/10/2021 Andrew J. Murphy
EVP Research
370   Disposition at $659.29 per share. 243,937
12/10/2021 Andrew J. Murphy
EVP Research
330   Disposition at $658.78 per share. 217,397
12/10/2021 Andrew J. Murphy
EVP Research
399   Disposition at $657.61 per share. 262,386
12/10/2021 Robert E. Landry
EVP Finance CFO
59   Disposition at $672.3 per share. 39,665
12/10/2021 Robert E. Landry
EVP Finance CFO
14   Disposition at $671.42 per share. 9,399
12/10/2021 Robert E. Landry
EVP Finance CFO
58   Disposition at $670.13 per share. 38,867
12/10/2021 Robert E. Landry
EVP Finance CFO
130   Disposition at $669.48 per share. 87,032
12/10/2021 Robert E. Landry
EVP Finance CFO
178   Disposition at $668.21 per share. 118,941
12/10/2021 Robert E. Landry
EVP Finance CFO
7   Disposition at $667.8 per share. 4,674
12/10/2021 Robert E. Landry
EVP Finance CFO
68   Disposition at $666.19 per share. 45,300
12/10/2021 Robert E. Landry
EVP Finance CFO
18   Disposition at $665.44 per share. 11,977
12/10/2021 Robert E. Landry
EVP Finance CFO
15   Disposition at $664.71 per share. 9,970
12/10/2021 Robert E. Landry
EVP Finance CFO
19   Disposition at $663.41 per share. 12,604
12/10/2021 Robert E. Landry
EVP Finance CFO
123   Disposition at $662.06 per share. 81,433
12/10/2021 Robert E. Landry
EVP Finance CFO
25   Disposition at $661.48 per share. 16,537
12/10/2021 Robert E. Landry
EVP Finance CFO
4   Disposition at $659.49 per share. 2,637
12/10/2021 Robert E. Landry
EVP Finance CFO
11   Disposition at $658.52 per share. 7,243
12/10/2021 Robert E. Landry
EVP Finance CFO
50   Disposition at $657.53 per share. 32,876
12/10/2021 Robert E. Landry
EVP Finance CFO
2   Disposition at $656.46 per share. 1,312
12/10/2021 Robert E. Landry
EVP Finance CFO
1,384   Derivative/Non-derivative trans. at $664.34 per share. 919,446
12/10/2021 Robert E. Landry
EVP Finance CFO
1,500   Derivative/Non-derivative trans. at $555.67 per share. 833,505
12/09/2021 Andrew J. Murphy
EVP Research
9,378   Derivative/Non-derivative trans. at $657.11 per share. 6,162,377
12/09/2021 Robert E. Landry
EVP Finance CFO
3,469   Derivative/Non-derivative trans. at $657.11 per share. 2,279,514
12/09/2021 Joseph J. LaRosa
EVP General Counsel and Secret
19,772   Derivative/Non-derivative trans. at $657.11 per share. 12,992,378
12/09/2021 Marc Tessier-Lavigne
Director
3,784   Disposition at $665 per share. 2,516,360
12/09/2021 Andrew J. Murphy
EVP Research
16,500   Derivative/Non-derivative trans. at $52.03 per share. 858,495
12/09/2021 Robert E. Landry
EVP Finance CFO
4,250   Derivative/Non-derivative trans. at $399.66 per share. 1,698,555
12/09/2021 Joseph J. LaRosa
EVP General Counsel and Secret
30,000   Derivative/Non-derivative trans. at $179.13 per share. 5,373,900
12/09/2021 Marc Tessier-Lavigne
Director
3,784   Derivative/Non-derivative trans. at $371.4 per share. 1,405,377
12/08/2021 P. Roy Vagelos
Director
1,861   Award at $0 per share. 0
12/08/2021 Neil Stahl
EVP Research and Development
2,926   Award at $0 per share. 0
12/08/2021 Andrew J. Murphy
EVP Research
3,462   Award at $0 per share. 0
12/08/2021 Christopher Robert Fenimore
SVP Controller
1,859   Award at $0 per share. 0
12/08/2021 Daniel P. van Plew
EVP & General Mgr, Industrial
4,344   Award at $0 per share. 0
12/08/2021 Robert E. Landry
EVP Finance CFO
3,971   Award at $0 per share. 0
12/08/2021 Joseph J. LaRosa
EVP General Counsel and Secret
3,338   Award at $0 per share. 0
12/08/2021 Marion McCourt
EVP Commercial
3,338   Award at $0 per share. 0
12/03/2021 Neil Stahl
EVP Research and Development
50,352   Derivative/Non-derivative trans. at $632.45 per share. 31,845,122
12/03/2021 Neil Stahl
EVP Research and Development
72,500   Derivative/Non-derivative trans. at $179.13 per share. 12,986,925
12/01/2021 Arthur Frederick Ryan
Director
6   Disposition at $641.23 per share. 3,847
12/01/2021 Arthur Frederick Ryan
Director
5   Disposition at $640.47 per share. 3,202
12/01/2021 Arthur Frederick Ryan
Director
24   Disposition at $639.49 per share. 15,347
12/01/2021 Arthur Frederick Ryan
Director
12   Disposition at $638.62 per share. 7,663
12/01/2021 Arthur Frederick Ryan
Director
22   Disposition at $637.75 per share. 14,030
12/01/2021 Arthur Frederick Ryan
Director
1   Disposition at $636.5 per share. 636
12/01/2021 Arthur Frederick Ryan
Director
9   Disposition at $635.36 per share. 5,718
12/01/2021 Arthur Frederick Ryan
Director
11   Disposition at $634.56 per share. 6,980
12/01/2021 Arthur Frederick Ryan
Director
2   Disposition at $633.47 per share. 1,266
12/01/2021 Arthur Frederick Ryan
Director
7   Disposition at $632.63 per share. 4,428
12/01/2021 Arthur Frederick Ryan
Director
1   Disposition at $631.15 per share. 631
12/01/2021 Marion McCourt
EVP Commercial
1,000   Disposition at $639.13 per share. 639,130
12/01/2021 Marion McCourt
EVP Commercial
1,000   Derivative/Non-derivative trans. at $342.93 per share. 342,930
/news/latest/company/us/regn

MarketWatch News on REGN

  1. How Omicron Is Changing Vaccine and Therapeutic Strategies

    10:10 a.m. Jan. 25, 2022

    - Josh Nathan-Kazis

  2. FDA halts use of antibody drugs that don’t work against omicron

    6:04 p.m. Jan. 24, 2022

    - Associated Press

  3. Glaxo and Vir Sell 600,000 Covid Antibody Doses to U.S.

    9:02 a.m. Jan. 11, 2022

    - Josh Nathan-Kazis

  4. Regeneron Pharmaceuticals downgraded to underperform from neutral at BofA Securities

    11:26 a.m. Jan. 5, 2022

    - Tomi Kilgore

  5. Tesla Gets 2022 Off to a Fast Start

    7:29 a.m. Jan. 3, 2022

  6. Omicron may sideline two leading drugs used to treat COVID-19

    5:26 p.m. Dec. 19, 2021

    - Associated Press

  7. Loading more headlines...
/news/nonmarketwatch/company/us/regn

Other News on REGN

  1. LABU - A Compelling Biotech Trade

    4:24 p.m. Jan. 26, 2022

    - Seeking Alpha

  2. Covid-19 Hospitalizations Continue to Fall in U.S.

    7:03 a.m. Jan. 25, 2022

    - Bertrand Benoit

  3. ASLAN (ASLN) Starts Phase IIb Study in Atopic Dermatitis

    10:55 a.m. Jan. 21, 2022

    - Zacks.com

  4. Loading more headlines...

At a Glance

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591-6707

Phone

1 9148477000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$8.50B

Net Income

$3.51B

2020 Sales Growth

8.1%

Employees

9,123

/news/pressrelease/company/us/regn

Press Releases on REGN

  1. Regeneron Pharmaceuticals REGN Trading Advice

    3:19 a.m. Jan. 28, 2022

    - Stock Traders Daily

  2. Promising Results Continue to Develop Optimism in Fight Against Cancers

    11:01 a.m. Jan. 27, 2022

    - Financial News Media

  3. How To Trade Regeneron Pharmaceuticals REGN

    11:04 a.m. Jan. 18, 2022

    - Stock Traders Daily

  4. Nasdaq 100 Movers: PTON, VRTX

    10:25 a.m. Jan. 10, 2022

    - MarketNewsVideo.com

  5. Regeneron Pharmaceuticals REGN Technical Analysis

    8:05 p.m. Dec. 29, 2021

    - Stock Traders Daily

  6. Loading more headlines...
Link to MarketWatch's Slice.